U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
Form 10-QSB
[X] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act
of 1934
For the quarterly period ended November 30, 1996
or
[ ] Transition report under Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Transition Period from _________ to ________.
Commission File No. 0-21354
ENDOGEN, INC.
(Exact name of Small Business Issuer as specified in charter)
Massachusetts 04-2789249
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
30 Commerce Way
Woburn, Massachusetts 01801-1059
(Address of principal executive offices)
(617) 937-0890
(Issuer's telephone number, including area code)
Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date.
Title Shares Outstanding as of January 3, 1997
---------------------------- ----------------------------------------
Common Stock, $0.01 par value 2,974,434
Transitional Small Business Disclosure Format (check one):
Yes No X
--- ---
Exhibit index located on page 12
Page 1 of 12
<PAGE>
ENDOGEN, INC.
FORM 10-QSB
QUARTER ENDED NOVEMBER 30, 1996
TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION Number
- ------------------------------ ------
Item 1 - Financial Statements (Unaudited)
Condensed Balance Sheet
November 30, 1996 and May 31, 1996...............................3
Condensed Statement of Operations
for the three months ended November 30, 1996 and 1995 and
for the six months ended November 30, 1996 and 1995..............4
Condensed Statement of Cash Flows
for the six months ended November 30, 1996 and 1995..............5
Notes to Condensed Financial Statements..............................6
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations........................8
PART II - OTHER INFORMATION
- ---------------------------
Item 4 - Submission of Matters to a Vote of Security Holders.............10
Item 6 - Exhibits and Reports on Form 8-K................................10
Signatures.............................................................. 11
Index To Exhibits........................................................12
Page 2 of 12
<PAGE>
PART I - Item 1
Financial Statements
ENDOGEN, INC.
CONDENSED BALANCE SHEET
<TABLE>
<CAPTION>
November 30, May 31,
1996 1996
------------ -------
(unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 405,342 $ 763,739
Accounts receivable, net of allowance for
doubtful accounts of $20,000 at
November 30, 1996 and May 31, 1996, 1,517,432 1,280,280
Accounts receivable - stockholder 68,496 149,067
Inventories 1,577,128 1,289,902
Prepaid expenses and other current assets 218,989 265,622
----------- ----------
Total current assets 3,787,387 3,748,610
Fixed assets, net 2,092,164 1,894,982
Patents and license costs, net 195,960 205,120
Other assets 633,753 707,668
----------- ----------
2,921,877 2,807,770
----------- ----------
$ 6,709,264 $6,556,380
=========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Borrowings under line of credit $ 50,000 $ -
Current portion of notes payable - bank 37,814 64,723
Current portion of convertible note payable 400,596 400,596
Current portion of term loan payable to a bank 133,333 -
Current portion of capital lease and other
note payable - 13,355
Accounts payable and accrued expenses 1,205,347 1,126,338
----------- ----------
Total current liabilities 1,827,090 1,605,012
----------- ----------
Borrowings under line of credit - 450,000
Notes payable - bank 2,181 7,633
Term loan payable to a bank 266,667 -
Convertible note payable 1,402,084 1,602,382
----------- ----------
1,670,932 2,060,015
----------- ----------
Stockholders' equity:
Common stock, $.01 par value; 10,000,000 and
5,000,000 shares authorized; 2,974,434 and
2,949,346 shares issued and outstanding at
November 30, 1996 and May 31, 1996,
respectively. 29,744 29,493
Additional paid-in capital 4,200,211 4,149,740
Accumulated deficit (1,018,713) (1,287,880)
---------- -----------
Total stockholders equity 3,211,242 2,891,353
---------- -----------
$6,709,264 $ 6,556,380
========== ===========
</TABLE>
See notes to condensed unaudited financial statements
Page 3 of 12
<PAGE>
ENDOGEN, INC.
CONDENSED STATEMENT OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
November 30, November 30,
1996 1995 1996 1995
----------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
REVENUE:
Product sales $2,398,533 $1,315,778 $4,513,669 $2,631,198
Product sales to stockholder 79,097 109,218 190,442 215,358
----------
---------- ---------- ----------
2,477,630 1,424,996 4,704,111 2,846,556
---------- ---------- ---------- ----------
COSTS AND EXPENSES:
Cost of sales 770,993 410,373 1,532,824 867,908
Cost of sales to stockholder 33,853 44,779 81,407 88,204
Selling, general & administrative 1,094,466 644,776 2,020,383 1,293,456
Research and development 332,750 249,903 629,896 501,287
---------- ---------- ---------- ----------
2,232,062 1,349,831 4,264,510 2,750,855
---------- ---------- ---------- ----------
Income from operations 245,568 75,165 439,601 95,701
Interest income (expense), net (42,189) (3,217) (120,434) 677
---------- ---------- ---------- ----------
Net income before provision
for income taxes 203,379 71,948 319,167 96,378
Provision for income taxes 50,000 - 50,000 -
---------- ---------- ---------- ----------
Net income $ 153,379 $ 71,948 $ 269,167 $ 96,378
========== ========== ========== ==========
Net income per share $ 0.05 $ 0.02 $ 0.08 $ 0.03
========== ========== ========== ==========
Weighted average shares
outstanding 3,257,576 3,105,894 3,250,665 3,061,311
========== ========== ========== ==========
</TABLE>
See notes to condensed unaudited financial statements
Page 4 of 12
<PAGE>
ENDOGEN, INC.
CONDENSED STATEMENT OF CASH FLOWS
Increase (Decrease) in Cash and Cash Equivalents
(Unaudited)
<TABLE>
<CAPTION>
Six Months Ended
November 30,
1996 1995
---------- -----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 269,167 $ 96,378
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 375,362 126,859
(Increase) decrease in accounts receivable (237,152) 50,037
Decrease (increase) in accounts receivable - stockholder 80,571 (91,400)
Increase in inventories (287,226) (51,700)
Decrease (increase) in prepaid expenses and other assets 73,384 (25,750)
Increase in patent and license costs (20,500) (26,672)
Increase in accounts payable and accrued expenses 79,009 104,583
---------- ----------
Net cash provided by operating activities 332,615 182,335
---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of fixed assets (495,720) (139,981)
---------- ----------
Net cash used for investing activities (495,720) (139,981)
---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of capital lease obligations and other note payable, net (646,014) (294,804)
Proceeds from borrowings under term loan payable to a bank 400,000 -
Proceeds from issuance of common stock 50,722 198,627
---------- ----------
Net cash used for financing activities (195,292) (96,177)
---------- ----------
Net decrease in cash and cash equivalents (358,397) (53,823)
Cash and cash equivalents, beginning of period 763,739 1,303,959
---------- ----------
Cash and cash equivalents, end of period $ 405,342 $1,250,136
========== ==========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest $ 125,838 $ 20,033
========== ==========
Cash paid for income taxes $ 50,000 $ --
========== ==========
</TABLE>
See notes to condensed unaudited financial statements
Page 5 of 12
<PAGE>
ENDOGEN, INC.
NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS
1. Basis of Presentation
The unaudited condensed financial statements of Endogen, Inc. (the
"Company" or "Endogen") include, in the opinion of management, all
adjustments (consisting of normal and recurring adjustments) necessary for
a fair presentation of the Company's financial position as of November 30,
1996 and the results of operations for the three and six month periods
ended November 30, 1996 and 1995. The results of operations are not
necessarily indicative of results for a full year.
These financial statements should be read in conjunction with the
financial statements contained in the Company's Form 10-K filed with the
Securities and Exchange Commission (the "SEC") on August 29, 1996 pursuant
to the Securities Exchange Act of 1934, as amended. Certain information
and footnote disclosures normally included in the financial statements
prepared in accordance with generally accepted accounting principles have
been condensed or omitted pursuant to the SEC rules and regulations.
2. Summary of Significant Accounting Policies
Net Income Per Share
Net income per share has been determined by taking net income divided by
the weighted average common shares and common share equivalents
outstanding during the period.
Change in Estimate
Effective September 1, 1996, the Company changed its estimate of the
remaining service life of certain fixed assets. The effect of the change
in estimate was a decrease in depreciation expense of approximately
$53,000 and an increase in earnings per share of $.02 for the three months
ended November 30, 1996.
3. Inventories
Inventories consist of the following:
November 30, May 31,
1996 1996
------------ ------------
Raw materials and supplies $ 704,036 $ 294,176
Work in process 436,311 314,976
Finished goods 436,781 680,750
---------- -----------
$1,577,128 $1,289,902
========== ===========
4. Fixed Assets
Fixed assets consist of the following:
November 30, May 31,
1996 1996
----------- -----------
Laboratory equipment $ 942,400 $ 896,056
Computer and office equipment 690,664 603,540
Leasehold improvements 1,307,988 945,736
---------- ----------
2,941,052 2,445,332
Accumulated depreciation and amortization (848,888) (550,350)
---------- ----------
$2,092,164 $1,894,982
========== ==========
Page 6 of 12
<PAGE>
Endogen, Inc.
Notes to Condensed Unaudited Financial Statements
5. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consist of the following:
November 30, May 31,
1996 1996
------------ --------
Accounts payable $ 696,544 $ 624,043
Accrued wages 178,172 138,204
Accrued royalties 173,024 147,357
Accrued professional fees 126,147 216,734
Accrued interest 31,460 --
---------- ----------
$1,205,347 $1,126,338
========== ==========
6. Common Stock
On November 6, 1996, the stockholders of the Company approved an increase
in the number of authorized shares of common stock from 5,000,000 to
10,000,000 shares.
Page 7 of 12
<PAGE>
ENDOGEN, INC.
PART I - Item 2
Management's Discussion and Analysis of Financial Condition and Results of
Operations
The following discussion includes forward-looking statements, including, but not
limited to, statements with respect to the Company's future financial
performance, operating results, plans and objectives. Actual results may differ
materially from those currently anticipated depending upon a variety of factors.
Endogen, Inc. ("Endogen" or the "Company") is principally engaged in the
development, manufacture and sale of specialty reagents and immuno-assay test
kits for pharmaceutical, biotechnology and biomedical research. These products
include over 200 specialty reagents and 49 immuno-assay test kits that measure
immune system function in human, mouse, rat, rabbit or porcine samples. Products
are sold directly in the United States and through distributors in over 40
foreign countries.
Results of Operations
For the six months ended November 30, 1996, product revenues increased 65% to
$4,704,111 from $2,846,556 in the same period last year. Revenues in the quarter
ended November 30, 1996 increased 74% to $2,477,630 from $1,424,996 in the same
quarter in 1995. The growth is attributable to increased sales volume from
existing Endogen product lines, new product introductions and product lines
acquired through the Company's acquisition of T Cell Diagnostics ("TCD") in
March 1996.
Cost of sales was $1,614,231 for the six months ended November 30, 1996 compared
with $956,112 for the same period last year. As a percentage of product
revenues, cost of sales was 34% in each of the six-month periods ended November
30, 1996 and 1995, respectively. Similarly, cost of sales was $804,846 or 32% of
revenues in the second quarter ended November 30, 1996 versus $455,152 or 32% in
the same quarter in 1995.
Research and development expense was $629,896 for the six months ended November
30, 1996 versus $501,287 for the same period last year, an increase of $128,609.
As a result of the growth of Endogen's revenues, research and development
expense decreased as a percentage of revenues to 13% for the six months ended
November 30, 1996 from 18% for the same period last year. For the three months
ended November 30, 1996, research and development expense was $332,750 or 13% of
revenues versus $249,903 or 18% of revenues for the prior year quarter. Future
research and development spending could, however, be expected to more closely
approach historical levels. Endogen plans to continue to spend heavily on
research and development in order to develop new products and to upgrade
existing products.
Selling, general and administrative expense was $2,020,383 for the six months
ended November 30, 1996 compared with $1,293,456 for the same period last year.
The increase of $726,927 is due primarily to increases in sales and marketing
staffing and activities. As a percentage of product revenues, selling, general
and administrative expense decreased to 43% of revenues for the six months ended
November 30, 1996 compared with 45% for the same period last year. This
improvement is attributable to improved efficiencies stemming from the TCD
acquisition and increased product revenues. For the three months ended November
30, 1996, selling, general and administrative expense was $1,094,466 or 44% of
revenues versus $644,776 or 45% of revenues in the comparable 1995 quarter.
Net interest expense was $120,434 for the six months ended November 30, 1996
compared with net interest income of $677 for the same period last year. The
increase in interest expense is due primarily to a convertible subordinated note
in the original principal amount of $2,002,978 issued by Endogen in connection
with the TCD acquisition in March 1996 and borrowings under a term note payable
with a bank.
The Company's effective tax rate is 16% for the three and six months ended
November 30, 1996. The effective rate is a result of 1997 operating income and
expected utilization of the Company's net operating loss and research and
development tax credit carryforwards. The Company did not have a provision for
income taxes during 1996 due to cumulative operating losses.
Page 8 of 12
<PAGE>
ENDOGEN, INC.
Liquidity and Capital Resources
The substantial growth of Endogen's business has led to increased liquidity
requirements to fund working capital needs and capital expenditures. This
includes financing inventories and accounts receivable to support the Company's
growing operations, as well as purchases of new laboratory equipment and
leasehold improvements to support new product development. Endogen has financed
its liquidity needs primarily through cash from operations, a working capital
line of credit with a bank and a term loan payable to a bank.
At November 30, 1996, Endogen's cash position was $405,342, a decrease of
$358,397 from May 31, 1996. At May 31, 1996, Endogen had utilized $450,000 of a
$500,000 working capital line of credit with a bank. On August 28, 1996, the
Company refinanced its existing line of credit with a bank, providing for
maximum borrowings of $850,000. Outstanding borrowings with this bank under a
line of credit totaled $50,000 at November 30, 1996 and outstanding borrowings
under a term loan agreement totaled $400,000 at November 30, 1996.
Based on management's current projections, Endogen believes that its financial
resources and cash flows from operations, together with the bank credit line and
term loan currently available, will be sufficient to finance its current and
planned operations for at least the next twelve months. There can be no
assurance, however, that the Company will not require additional working capital
and, if it does require such capital, that such capital will be available to the
Company on acceptable terms, if at all.
Certain Factors That May Affect Future Results
The Company does not provide forecasts of the future financial performance of
the Company. However, from time to time, information provided by the Company or
statements made by its employees may contain "forward-looking" information that
involve risks and uncertainties. In particular, statements contained in this
Form 10-QSB that are not historical facts constitute forward-looking statements
and are made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The Company's actual results of operations and
financial condition have varied and may in the future vary significantly from
those stated in any forward-looking statements. The Company's future operating
results are subject to risks and uncertainties and are dependent upon many
factors, including, without limitation, the Company's ability to (i) meet its
working capital and future liquidity needs, (ii) successfully implement its
strategic growth strategies, (iii) understand, anticipate and respond to rapidly
changing technologies, market trends and customer needs, (iv) develop,
manufacture and deliver high quality, technologically advanced products on a
timely basis to withstand competition from competitors which may have greater
financial, information gathering and marketing resources than the Company, (v)
obtain and protect licensing and intellectual property rights necessary for the
Company's technology and product development and on terms favorable to the
Company, and (vi) recruit and retain highly talented professionals in a
competitive job market. The Company's ability to market and sell its products
could also be adversely affected by the emergence of new competitors in the
market place and by changes resulting in increased government regulation of the
manufacture and sale of its products. In addition, a significant portion of the
Company's revenues are attributable to international customers, which may be
adversely affected by factors including fluctuations in exchange rates, adverse
political and economic conditions, tariff regulation, and difficulties in
obtaining export licenses. Each of these factors, and others, are discussed from
time to time in the filings made by the Company with the Securities and Exchange
Commission, including, but not limited to, the Company's Annual Report on Form
10-K filed on August 29, 1996 and its Quarterly Report on Form 10-QSB filed on
October 15, 1996.
Page 9 of 12
<PAGE>
ENDOGEN, INC.
PART II - OTHER INFORMATION
Item 4 - Submission of Matters to a Vote of Security Holders
The annual meeting of Stockholders of Endogen, Inc. was held on
November 6, 1996. A vote was proposed (1) to elect members of the
Company's Board of Directors to serve for the ensuing year or until
their successors are elected and qualified, or until their earlier
resignation or removal; (2) to amend the Company's Restated Articles of
Organization to increase the number of authorized shares of Common
Stock, $.01 par value per share, from 5,000,000 to 10,000,000 shares;
and (3) to ratify the selection of the firm of Price Waterhouse LLP as
independent auditors for the fiscal year ending May 31, 1997. The
shareholder voting results are as follows:
<TABLE>
<CAPTION>
Votes Votes Votes Broker
for against abstained Non-votes
<S> <C> <C> <C> <C>
(1) Election of:
Owen A. Dempsey 2,504,959 77,751 - -
Wallace G. Dempsey 2,505,027 77,683 - -
Irwin J. Gruverman 2,394,027 188,683 - -
Hayden H. Harris 2,504,734 77,976 - -
Wolfgang Woloszczuk 2,505,027 77,683 - -
(2) Amend Restated Articles of Organization
2,458,789 105,200 18,721 -
(2) Ratify Price Waterhouse LLP 2,568,048 4,203 10,459 -
</TABLE>
Item 6 - Exhibits and Reports on Form 8-K
(a) - EXHIBITS
--------
3.1 Restated Articles of Organization
11.1 Statement Re: Computation of Per Share Earnings
27.1 Financial Data Schedule
(b) - REPORTS ON FORM 8-K
-------------------
No reports on Form 8-K have been filed during the quarter for which this
report is filed.
Page 10 of 12
<PAGE>
ENDOGEN, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ENDOGEN, INC.
BY:
Date: January 13, 1997 /s/ Owen A. Dempsey
--------------------------------
Owen A. Dempsey
Director, President and
Chief Executive Officer
Date: January 13, 1997 /s/ Avery W. Catlin
--------------------------------
Avery W. Catlin
Vice President, Finance, Treasurer
and Chief Financial Officer
(Principal Financial and
Chief Accounting Officer)
Page 11 of 12
<PAGE>
ENDOGEN, INC.
INDEX TO EXHIBITS
Exhibit Number Description Page
3.1 Restated Articles of Organization...........................
11.1 Statement regarding Computation of Earnings per Share.......
27.1 Financial Data Schedule.....................................
Page 12 of 12
EXHIBIT 3.1
FEDERAL IDENTIFICATION
NO. 04-2789249
----------
The Commonwealth of Massachusetts
William Francis Galvin
Secretary of the Commonwealth
One Ashburton Place, Boston, Massachusetts 02108-1512
ARTICLES OF AMENDMENT
(General Laws, Chapter 156B, Section 72)
We, Owen A. Dempsey , *President,
---------------------------------------------------------------
and Daniel Burns , *Clerk,
---------------------------------------------------------------
of Endogen, Inc. ,
----------------------------------------------------------------------------
(Exact name of corporation)
located at 30 Commerce Way, Woburn, MA 01801 ,
---------------------------------------------------------------------
(Street address of corporation in Massachusetts)
certify that these Articles of Amendment affecting articles numbered:
Article 3
- -------------------------------------------------------------------------------
(Number those articles 1, 2, 3, 4, 5 and/or 6 being amended)
of the Articles of Organization were duly adopted at a meeting held on November
6, 1996, by vote of:
2,458,789 shares of Common of 2,955,527 shares outstanding,
- ------------- ------------- --------------
(type, class & series, if any)
shares of of shares outstanding, and
- ------------- ------------- ------------
(type, class & series, if any)
shares of of shares outstanding.
- ------------- ------------- ------------
(type, class & series, if any)
1**being at least a majority of each type, class or series outstanding and
entitled to vote thereon
*Delete the inapplicable words. **Delete the inapplicable clause.
1 For amendments adopted pursuant to Chapter 156B, Section 70.
2 For amendments adopted pursuant to Chapter 156B, Section 71.
Note: If the space provided under any article or item on this form is
insufficient, additions shall be set forth on one side only of separate 8 1/2 x
11 sheets of paper with a left margin of at least 1 inch. Additions to more than
one article may be made on a single sheet as long as each article requiring each
addition is clearly indicated.
<PAGE>
To change the number of shares and the par value (if any) of any type, class or
series of stock which the corporation is authorized to issue, fill in the
following:
The total presently authorized is:
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------------------------------------
WITHOUT PAR VALUE STOCKS WITH PAR VALUE STOCKS
- ---------------------------------------------------------------------------------------------------------------
TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE
- ---------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common: None Common: 5,000,000 $.01
- ---------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------
Preferred: None Preferred: None None
- ---------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------
</TABLE>
Change the total authorized to:
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------------------------------------
WITHOUT PAR VALUE STOCKS WITH PAR VALUE STOCKS
- ---------------------------------------------------------------------------------------------------------------
TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE
- ---------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common: None Common: 10,000,000 $.01
- ---------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------
Preferred: None Preferred: None None
- ---------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------
<PAGE>
The foregoing amendment(s) will become effective when these Articles of
Amendment are filed in accordance with General Laws, Chapter 156B, Section 6
unless these articles specify, in accordance with the vote adopting the
amendment, a later effective date not more than thirty days after such filing,
in which event the amendment will become effective on such later date.
Later effective date: .
SIGNED UNDER THE PENALTIES OF PERJURY, this 7th day of November , 1996 ,
------- ------------ -------
/s/ Owen A. Dempsey , *President,
- ----------------------------------------------------------------
/s/ Daniel Burns , *Clerk
- ----------------------------------------------------------------
*Delete the inapplicable words.
<PAGE>
THE COMMONWEALTH OF MASSACHUSETTS
ARTICLES OF AMENDMENT
(General Laws, Chapter 156B, Section 72)
=====================================================
I hereby approve the within Articles of Amendment and,
the filing fee in the amount of $5,000 having been
paid, said articles are deemed to have been filed with
me this 2nd day of December 1996.
Effective date:
-------------------------------------
/s/ William Francis Galvin
WILLIAM FRANCIS GALVIN
Secretary of the Commonwealth
TO BE FILLED IN BY CORPORATION
Photocopy of document to be sent to:
Walter H. Stowell, III
----------------------------------------
Testa, Hurwitz & Thibeault, LLP
High Street Tower
----------------------------------------
125 High Street
Boston, MA 02110
----------------------------------------
(617) 248-7000
<PAGE>
The Commonwealth of Massachusetts
MICHAEL JOSEPH CONNOLLY FEDERAL IDENTIFICATION
Secretary of State NO. 38-3090331
----------------
ONE ASHBURTON PLACE FEDERAL IDENTIFICATION
BOSTON, MASS. 02108 NO. 04-2789249
----------------
ARTICLES OF MERGER*
Pursuant to General Laws, Chapter 156B, Section 79
The fee for filing this certificate is prescribed by General Laws,
Chapter 156B, Section 114. Make checks payable to the
Commonwealth of Massachusetts.
MERGER* OF Diagnostics Holding Corp.
-------------------------
Endogen, Inc.
----------------------------------------
----------------------------------------
----------------------------------------
the constituent corporations
into
Endogen, Inc.
----------------------------------------
one of the constituent corporations* organized under the laws of Massachusetts
as specified in the agreement referred to in Paragraph 1 below.
The undersigned officers of each of the constituent corporations
certify under the penalties of perjury as follows:
1. An agreement of merger* has been duly adopted in compliance with the
requirements of subsections (b) and (c) of General Laws, Chapter 156B, Section
79, and will be kept as provided by subsection (c) thereof. The surviving*
corporation will furnish a copy of said agreement to any of its stockholders, or
to any person who was a stockholder of any constituent corporation, upon written
request and without charge.
2. The effective date of the merger* determined pursuant to the
agreement referred to in paragraph 1 shall be March 19, 1993.
3. (For a merger)
**The following amendments to the articles of organization of the
SURVIVING corporation have been affected pursuant to the agreement
of merger referred to in paragraph 1:
See Continuation Sheet 3
(a) The purposes of the RESULTING corporation are as follows:
*Delete the inapplicable words.
**If there are no provisions state "NONE."
NOTE: If the space provided under article 3 is insufficient, additions
shall be set forth on separate 8 1/2 x 11 inch sheets of paper,
leaving a left hand margin of at least 1 inch for binding.
Additions to more than one article may be continued on a single
sheet so long as each article requiring each such addition is
clearly indicated.
<PAGE>
(b) The total number of shares and the par value, if any, of each class
of stock which the resulting corporation is authorized is as follows:
- ---------------------------------------------------------------------------------------------------------------------
WITHOUT PAR VALUE WITH PAR VALUE
- ---------------------------------------------------------------------------------------------------------------------
CLASS OF STOCK NUMBER OF SHARES NUMBER OF SHARES PAR VALUE AMOUNT
- ---------------------------------------------------------------------------------------------------------------------
Preferred $
- ---------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------
Common
- ---------------------------------------------------------------------------------------------------------------------
** (c) If more than one class is authorized, a description of each of
the different classes of stock with, if any, the preferences, voting powers,
qualifications, special or relative rights or privileges as to each class
thereof and any series now established.
** (d) Other lawful provisions, if any, for the conduct and regulation
of the business and affairs of the corporation, for its voluntary dissolution,
for restrictions upon the transfer of shares of stock of any class, or for
limiting, defining, or regulating the powers of the corporation, or of its
directors or stockholders, or of any class of stockholders:
4. (This paragraph 4 may be deleted if the surviving* corporation is
organized under the laws of a state other than Massachusetts.)
The following information shall not for any purpose be treated as a permanent
part of the articles of organization of the surviving* corporation:
(a) The post office address of the initial principal office of the
surviving* corporation in Massachusetts is: 68 Fargo Street, Boston, MA 02210
(b) The name, residence and post office address of each of the initial
directors and President, Treasurer and Clerk of the surviving* corporation is as
follows:
Name Residence Post Office Address
President See Continuation Sheet 4 (b)
Treasurer
Clerk
Directors
(c) The date initially adopted on which the fiscal year of the
surviving* corporation ends is: May 31
(d) The date initially fixed in the by-laws for the Annual Meeting of
stockholders of the surviving* corporation is: October 31
*Delete the inapplicable words.
**If there are non provisions state "NONE."
NOTE: If the space provided under article 3 is insufficient, additions
shall be set forth on separate 81/2 x 11 sheets of paper, leaving
a left hand margin of at least 1 inch for binding. Additions to
more than one article may be continued on a single sheet so long
as each article requiring each such addition is clearly indicated.
<PAGE>
5. (This paragraph 5 may be deleted if the surviving* corporation is
organized under the laws of Massachusetts).
The surviving* corporation hereby agrees that it may be sued in the Commonwealth
of Massachusetts for any prior obligation of any constituent foreign corporation
qualified under General Laws, Chapter 181, and any obligations hereafter
incurred by the surviving* corporation, including the obligation created by
General Laws, Chapter 156B, Section 85, so long as any liability remains
outstanding against the corporation in the Commonwealth of Massachusetts, and it
hereby irrevocably appoints the Secretary of the Commonwealth as its agent to
accept service of process in any action for the enforcement of any such
obligation, including taxes, in the same manner as provided in Chapter 181.
*Delete the inapplicable words.
FOR MASSACHUSETTS CORPORATIONS
The undersigned President* and Clerk* of Endogen, Inc. a corporation
organized under the laws of Massachusetts further state under the penalties of
perjury that the agreement of merger* referred to in paragraph 1 has been duly
executed on behalf of such corporation and duly approved in the manner required
by General Laws, Chapter 156B, Section 79.
/s/ Owen A. Dempsey____________ President*
-------------------
/s/ Eileen Fleming__________________ Clerk*
------------------
FOR CORPORATIONS ORGANIZED OTHER THAN IN MASSACHUSETTS
The undersigned President+ and Secretary++ of Diagnostics Holding Corp.
a corporation organized under the laws of Delaware further state under the
penalties of perjury that the agreement of merger* referred to in paragraph 1,
has been duly adopted by such corporation in the manner required by the laws of
Delaware.
/s/Rod N. Raynovich +
-----------------------------------------
/s/Franco Tomasini ++
-------------------------------------------
* Delete the inapplicable words.
+ Specify the officer having powers and duties corresponding to those of
President or Vice President of a Massachusetts corporation organized under
General Laws, Chapter 156B.
++ Specify the officer having power and duties corresponding to the Clerk or
Assistant Clerk of such a Massachusetts corporation.
<PAGE>
THE COMMONWEALTH OF MASSACHUSETTS
ARTICLES OF MERGER
(General Laws, Chapter 156B, Section 79)
I hereby approve the within articles of merger and, the filing fee in
the amount of $3,800 having been paid, said articles are deemed to have been
filed with me this 19th day of March, 1993.
Effective Date /s/ Michael Joseph Connolly
3/19/93 ---------------------------
MICHAEL JOSEPH CONNOLLY
Secretary of State
TO BE FILLED IN BY CORPORATION
Photo Copy of Articles of Merger To Be Sent
TO: William J. Schnoor, Jr.
Testa, Hurwitz & Thibeault
53 State Street
Boston, MA 02109
Telephone (617) 248-7000
<PAGE>
Continuation Sheet 3
Article 3 of the Restated Articles of Organization of Endogen, Inc. is amended and restated in its entirety as
follows:
"3. The total number of shares and the par value, if any, of each class
of stock which the corporation is authorized to issue is as follows:
WITHOUT PAR VALUE WITH PAR VALUE
----------------- --------------
CLASS OF STOCK NUMBER OF SHARES NUMBER OF SHARES PAR VALUE
- -------------- ---------------- ---------------- ---------
<S> <C> <C> <C>
Preferred None None None
Common None 5,000,000 $0.01"
</TABLE>
Article 4 of the Restated Articles of Organization of Endogen, Inc. is
amended and restated in its entirety as follows:
"4. If more than one class is authorized, a description of each of
the different classes of stock with, if any, the preferences,
voting powers, qualifications, special or relative rights or
privileges as to each class thereof and any series now
established:
None."
<PAGE>
Continuation Sheet 4(b)
(b) The name, residence and post office address of each of the initial
directors and President, Treasurer and Clerk of the surviving corporation is as
follows:
<TABLE>
<CAPTION>
Name Residence Post Office Address
<S> <C> <C> <C>
President Owen A. Dempsey 9 Newton Street, #3 c/o Endogen, Inc.
Cambridge, MA 02139 68 Fargo Street
Boston, MA 02210
Treasurer Owen A. Dempsey Same as above Same as above
Clerk Eileen Fleming 92 Marlborough Street 92 Marlborough Street
Boston, MA 02116 Boston, MA 02116
Directors Owen A. Dempsey Same as above Same as above
Wallace G. Dempsey 487 Scarsdale Road 487 Scarsdale Road
Crestwood, NY 10707 Crestwood, NY 10707
Irving A. Berstein 42 Buckman Drive 42 Buckman Drive
Lexington, MA 02173 Lexington, MA 02173
Wolfgang Woloszczuk Biomedica GmbH Biomedica GmbH
Divischgasse 4 Divischgasse 4
A-1210 Vienna A-1210 Vienna
Austria Austria
Irwin Gruverman 16 Tanglewood Road 16 Tanglewood Road
Needham, MA 02194 Needham, MA 02194
Hayden Harris 13875 Waters Road 13875 Waters Road
Chelsea, MI 48116 Chelsea, MI 48116
Frank Gleason 25 Ramsay Road 25 Ramsay Road
Montclair, NJ 07042 Montclair, NJ 07042
</TABLE>
<PAGE>
THE COMMONWEALTH OF MASSACHUSETTS
MICHAEL JOSEPH CONNOLLY
Secretary of State FEDERAL IDENTIFICATION
ONE ASHBURTON PLACE, BOSTON, MASS: 02108 No. 04-2789249
RESTATED ARTICLES OF ORGANIZATION
General Laws, Chapter 156B, Section 74
This certificate must be submitted to the Secretary of the Commonwealth
within sixty days after the date of the vote of stockholders adopting the
restated articles of organization. The fee for filing this certificate is
prescribed by General Laws, Chapter 156B, Section 114. Make check payable to the
Commonwealth of Massachusetts.
---------------
We, Owen A. Dempsey , President
Eileen Fleming , Clerk
EndoGen, Inc.
- --------------------------------------------------------------------------------
(Name of Corporation)
located at 451 D Street, Boston, MA 02210 do hereby certify that the following
restatement of the articles of organization of the corporation was duly adopted
at a meeting held on November 21, 1990, by vote of
<TABLE>
<S> <C>
316,600 shares of Common out of 327,933 shares outstanding,
(Class of Stock)
shares of out of shares outstanding,
(Class of Stock)
shares of out of shares outstanding,
(Class of Stock)
</TABLE>
being at least two-thirds of each class of stock outstanding and entitled to
vote and of each class or series of stock adversely affected thereby:
1. The name by which the corporation shall be known is: -
EndoGen, Inc.
2. The purposes for which the corporation is formed are as
follows: -
To engage in the business of research related to and
development of proprietary biologic products for laboratory
and clinical use and to engage in any other business activity
now or hereafter permitted by the Commonwealth of
Massachusetts to a corporation organized under Chapter 156B of
its General Laws.
Note: If the space provided under any article or item on this form is
insufficient, additions shall be set forth on separate 8 1/2 x 11 sheets of
paper leaving a left hand margin of at least 1 inch for binding. Additions to
more than one article may be continued on a single sheet so long as each article
requiring each such addition is clearly indicated.
<PAGE>
3. The total number of shares and the par value, if any, of each
class of stock which the corporation is authorized to issue
is as follows:
<TABLE>
<CAPTION>
WITHOUT PAR VALUE WITH PAR VALUE
----------------- --------------
CLASS OF STOCK NUMBER OF SHARES NUMBER OF SHARES PAR VALUE
- -------------- ---------------- ---------------- ---------
<S> <C> <C> <C>
Preferred None 200,000 $0.10
Common None 1,000,000 $0.01
</TABLE>
*4. If more than one class is authorized, a description of each of
the different classes of stock with, if any, the preferences,
voting powers, qualifications, special or relative rights or
privileges as to each class thereof and any series now
established:
See Continuation Sheets 4A - 4O
*5. The restrictions, if any, imposed by the articles of
organization upon the transfer of shares of stock of any
class are as follows:
None; however, shares of stock of the corporation may be
subjected to restrictions on the transfer thereof under duly
adopted by-law provisions and/or under any agreement to which
the corporation shall be a party.
*6. Other lawful provisions, if any, for the conduct and
regulation of the business and affairs of the corporation, for
its voluntary dissolution, or for limiting, defining, or
regulating the powers of the corporation, or of its directors
or stockholders, or of any class of stockholders:
See Continuation Sheet 6A
*If there are no such provisions, state "None".
<PAGE>
*We further certify that the foregoing restated articles of
organization effect no amendments to the articles of organization of the
corporation as heretofore amended, except amendments to the following
articles _______________________________________________________________________
Articles 3, 4 and 6_____________________________________________________________
(*If there are no such amendments, state "None".)
Briefly describe amendments in space below:
The number of authorized shares of Common Stock with the rights
therefore set forth on Continuation Sheets 4A - 4O has been increased from
600,000 shares to 1,000,000 shares. A class of Preferred Stock has been created
with the preferences, voting powers, qualifications, and special or relative
rights or privileges set forth on Continuation Sheets 4A - 4O.
IN WITNESS WHEREOF AND UNDER THE PENALTIES OF PERJURY, we have hereto signed our
names this 21st day of November in the year 1990.
/s/ Owen A. Dempsey President
- ----------------------------------------------------------------------
/s/ Eileen Fleming Clerk
- ----------------------------------------------------------------------
<PAGE>
THE COMMONWEALTH OF MASSACHUSETTS
RESTATED ARTICLES OF ORGANIZATION
(General Laws, Chapter 156B, Section 74)
I hereby approve the within restated articles of
organization and, the filing fee in the amount of
$1,000 having been paid, said articles are deemed to
have been filed with me this 30th day of November,
1990.
/s/ Michael Joseph Connolly
MICHAEL JOSEPH CONNOLLY
Secretary of State
TO BE FILLED IN BY CORPORATION
PHOTOCOPY OF RESTATED ARTICLES OF ORGANIZATION TO BE SENT
TO:
William J. Schnoor, Jr
----------------------------------
Testa, Hurwitz & Thibeault
----------------------------------
53 State Street
----------------------------------
Exchange Place
----------------------------------
Boston, MA 02109
----------------------------------
Telephone: (617) 248-7000
----------------------------------
<PAGE>
Continuation Sheet 4A
A. SERIES A CONVERTIBLE PREFERRED STOCK
1. Number of Shares. The series of Preferred Stock designated and known
as "Series A Convertible Preferred Stock" shall consist of 200,000 shares.
2. Voting.
2A. General. Except as may be otherwise provided in these
terms of the Series A Convertible Preferred Stock or by law, the Series A
Convertible Preferred Stock shall vote together with all other classes and
series of stock of the Corporation as a single class on all actions to be taken
by the stockholders of the Corporation. Each share of Series A Convertible
Preferred Stock shall entitle the holder thereof to such number of votes per
share on each such action as shall equal the number of shares of Common Stock
(including fractions of a share) into which each share of Series A Convertible
Preferred Stock is then convertible.
2B. Board Size. The Corporation shall not, without the written
consent or affirmative vote of the holders of at least sixty-six and two-thirds
percent (66-2/3%) of the then outstanding shares of Series A Convertible
Preferred Stock, given in writing or by vote at a meeting, consenting or voting
(as the case may be) separately as a series, increase the maximum number of
directors constituting the Board of Directors to a number in excess of seven
(7).
2C. Board Seats. The holders of the Series A Convertible
Preferred Stock, voting as a separate series, shall be entitled to elect two (2)
directors of the Corporation. The holders of the Common Stock, voting as a
separate class, shall be entitled to elect three (3) directors of the
Corporation. Any remaining directors shall be such person(s), if any, who
receive(s) plurality vote of the holders of the Series A Convertible Preferred
Stock, voting as a separate series, and a plurality vote of the holders of the
Common Stock, voting as a separate class. Notwithstanding the foregoing or
anything else to the contrary provided in the Restated Articles of Organization,
if the Corporation fails or refuses, for any reason or for no reason, to reeem
on any of the Redemption Dates (as defined in paragraph 7) the then outstanding
shares of Series A Convertible Preferred Stock to be redeemed in accordance with
the terms and provisions of paragraph 7 and if the Corporation does not obtain
the approval of at least sixty-six and two-thirds percent (66-2/3%) of the then
outstanding shares of Series A Convertible Preferred Stock to such failure, the
holders of the Series A Convertible Preferred Stock, voting as a separate
series, shall be entitled to elect a majority of the directors of the
Corporation. At any meeting of stockholders the presence in person or by proxy
of the holders of a majority of the
<PAGE>
Continuation Sheet 4B
shares of Series A Convertible Preferred Stock then outstanding shall constitute
a quorum of the Series A Convertible Preferred Stock for the election of
directors to be elected solely by the holders of the Series A Convertible
Preferred Stock or jointly by the holders of the Series A Convertible Preferred
Stock and the holders of the Common Stock. A vacancy in any directorship elected
by the holders of the Series A Convertible Preferred Stock shall be filled only
by vote or written consent of the holders of the Series A Convertible Preferred
Stock and a vacancy in the directorship elected jointly by the holders of the
Series A Convertible Preferred Stock and the Common Stock shall be filled only
by vote or written consent of the Series A Convertible Preferred Stock and the
Common Stock as provided above. At any time after the voting power to elect a
majority of the Board of Directors shall have become vested in the holders of
Series A Convertible Preferred Stock as provided in this subparagraph 2C, the
President of the Corporation may, and upon the written request of any holder of
at least 10% of the then outstanding shares of Series A Convertible Preferred
Stock addressed to him at the principal office of the Corporation, shall, call a
special meeting of all stockholders for the election of directors, to be held at
the place and upon the notice provided in the by-laws of the Corporation for the
holding of meetings of stockholders. If such meeting shall not be so called
within ten days after personal service of the request, or within fifteen days
after mailing of the same by certified mail within the United States of America,
then the holders of at least a majority of the shares of Series A Convertible
Preferred Stock may designate in writing one of their number to call such
meeting, and the person so designated may call such meeting at the place and
upon the notice above provided, and for that purpose shall have access to the
stock books of the Corporation. At such meeting the holders of Series A
Convertible Preferred Stock, acting as a separate class, shall be entitled to
elect the minimum number of directors that shall constitute a majority of the
directors of the Corporation, and the holders of the Series A Convertible
Preferred Stock and the holders of the Common Stock, acting jointly as a single
class, shall be entitled to elect the remaining directors of the Corporation.
The terms of office of all persons who are directors of the Corporation at the
time of such meeting shall terminate upon the election at such meeting of
directors as described in the preceding sentence, and the persons so elected as
directors by such holders shall constitute the duly elected directors of the
Corporation.
3. Dividends. The holders of the Series A Convertible Preferred Stock
shall be entitled to receive, out of funds legally available therefor, when and
if declared by the Board of Directors, annual dividends at the rate per annum of
$.816 per share, adjusted to reflect any stock split, stock dividend,
combination, recapitalization or reorganization (the "Accruing Dividends") in
preference and priority to any payment of any dividend on shares of Common
Stock, or shares
<PAGE>
Continuation Sheet 4C
of any other class of stock ranking junior to the Series A Convertible Preferred
Stock in dividends or liquidation rights (the "Junior Shares"). Accruing
Dividends shall accrue from day to day, whether or not earned or declared, and
shall be cumulative. Such Accruing Dividends will be payable only (a) if, as and
when determined by a majority of the Board of Directors or (b) as provided in
paragraphs (4) and (7) below. As long as any shares of the Series A Convertible
Preferred Stock are outstanding, the Corporation shall not declare or pay any
dividend or make any other distribution upon any Junior Shares (except dividends
or distributions payable in stock of the Corporation ranking junior to the
Series A Convertible Preferred Stock as to dividends and ranking junior to the
Series A Convertible Preferred Stock in liquidation).
4. Liquidation. Upon any liquidation, dissolution or winding up of the
Corporation, whether voluntary or involuntary, the holders of the shares of
Series A Convertible Preferred Stock shall be entitled, before any distribution
or payment is made upon any stock ranking on liquidation junior to the Series A
Convertible Preferred Stock, to be paid an amount equal to the greater of (i)
$8.16 per share plus, in the case of each share, an amount equal to all Accruing
Dividends unpaid thereon (whether or not declared) and any other dividends
declared but unpaid thereon, computed to the date payment thereof is made
available, or (ii) such amount per share as would have been payable had each
such share been converted to Common Stock pursuant to paragraph 6 immediately
prior to such liquidation, dissolution or winding up, and the holders of Series
A Convertible Preferred Stock shall not be entitled to any further payment, such
amount payable with respect to one share of Series A Convertible Preferred Stock
being sometimes referred to as the "Liquidation Payment" and with respect to all
shares of Series A Convertible Preferred Stock being sometimes referred to as
the "Liquidation Payments". If upon such liquidation, dissolution or winding up
of the Corporation, whether voluntary or involuntary, the assets to be
distributed among the holders of Series A Convertible Preferred Stock shall be
insufficient to permit payment to the holders of Series A Convertible Preferred
Stock of the amount distributable as aforesaid, then the entire assets of the
Corporation to be so distributed shall be distributed ratably among the holders
of Series A Convertible Preferred Stock. Upon any such liquidation, dissolution
or winding up of the Corporation, after the holders of Series A Convertible
Preferred Stock shall have been paid in full the amounts to which they shall be
entitled, the remaining net assets of the Corporation may be distributed to the
holders of stock ranking on liquidation junior to the Series A Convertible
Preferred Stock. Written notice of such liquidation, dissolution or winding up,
stating a payment date, the amount of the Liquidation Payments and the place
where said Liquidation Payments shall be payable, shall be given by mail,
postage prepaid, or by telex to non-U.S. residents, not less than 20 days prior
to the payment date stated therein, to the holders of record of Series A
Convertible Preferred Stock, such notice to be addressed to each such holder at
its address as shown by the records of the Corporation.
<PAGE>
Continuation Sheet 4D
The consolidation or merger of the Corporation into or with any other entity or
entities which results in the issuance or exchange of at least a majority of the
outstanding shares of the Corporation for securities or other consideration
issued or paid or caused to be issued or paid by any such entity or affiliate
thereof, and the sale or transfer by the Corporation of all or substantially all
its assets, shall be deemed to be a liquidation, dissolution or winding up of
the Corporation within the meaning of the provisions of this paragraph 4. For
purposes hereof, the Common Stock shall rank on liquidation junior to the Series
A Convertible Preferred Stock.
5. Restrictions. At any time when shares of Series A Convertible
Preferred Stock are outstanding, except where the vote or written consent of the
holders of a greater number of shares of the Corporation is required by law or
by the Restated Articles of Organization, and in addition to any other vote
required by law or the Restated Articles of Organization, without the approval
of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the
then outstanding shares of Series A Convertible Preferred Stock, given in
writing or by vote at a meeting, consenting or voting (as the case may be)
separately as a series, the Corporation will not:
5A. Create or authorize the creation of any additional class
or series of preferred stock or security convertible into Common Stock unless
the same ranks junior to the Series A Convertible Preferred Stock as to (i) the
distribution of assets on the liquidation, dissolution or winding up of the
Corporation, (ii) the payment of dividends on such security and (iii) the
redemption of such security, whether any such creation, authorization or
increase shall be by means of amendment to the Restated Articles of Organization
or by merger, consolidation or otherwise;
5B. Consent to any liquidation, dissolution or winding up of
the Corporation, or consolidate or merge into or with any other entity or
entities, or sell or transfer all or substantially all its assets;
5C. Amend, alter or repeal its Restated Articles of
Organization or By-laws, or take any other actions which adversely affects, as
defined in the Massachusetts Business Corporate Law, the Series A Convertible
Preferred Stock;
5D. Purchase or set aside any sums for the purchase of any
shares of Common Stock, except for repurchases at cost pursuant to stock vesting
agreements or stock restriction agreements with employees, other stockholders or
consultants; or
5E. Acquire (i) any entity, (ii) substantially all of the
assets of an entity, or (iii) securities of an entity, which is outside of the
research biologicals business.
<PAGE>
Continuation Sheet 4E
6. Conversions. The holders of shares of Series A Convertible Preferred
Stock shall have the following conversion rights:
6A. Right to Convert. Subject to the terms and conditions of
this paragraph 6, the holder of any share or shares of Series A Convertible
Preferred Stock shall have the right, at its option at any time, to convert any
such shares of Series A Convertible Preferred Stock (except that upon any
liquidation of the Corporation the right of conversion shall terminate at the
close of business on the business day fixed for payment of the amount
distributable on the Series A Convertible Preferred Stock) into such number of
fully paid and nonassessable shares of Common Stock as is obtained by (i)
multiplying the number of shares of Series A Convertible Preferred Stock so to
be converted by $8.16 and (ii) dividing the result by the conversion price of
$8.16 per share or, in case an adjustment of such price has taken place pursuant
to the further provisions of this paragraph 6, then by the conversion price as
last adjusted and in effect at the date any share or shares of Series A
Convertible Preferred Stock are surrendered for conversion (such price, or such
price as last adjusted, being referred to as the "Conversion Price"). Such
rights of conversion shall be exercised by the holder thereof by giving written
notice that the holder elects to convert a stated number of shares of Series A
Convertible Preferred Stock into Common Stock and by surrender of a certificate
or certificates for the shares so to be converted to the Corporation at its
principal office (or such other office or agency of the Corporation as the
Corporation may designate by notice in writing to the holders of the Series A
Convertible Preferred Stock) at any time during its usual business hours on the
date set forth in such notice, together with a statement of the name or names
(with address) in which the certificate or certificates for shares of Common
Stock shall be issued.
6B. Issuance of Certificates; Time Conversion Effected.
Promptly after the receipt of the written notice referred to in subparagraph 6A
and surrender of the certificate or certificates for the share or shares of
Series A Convertible Preferred Stock to be converted, the Corporation shall
issue and deliver, or cause to be issued and delivered, to the holder,
registered in such name or names as such holder may direct, a certificate or
certificates for the number of whole shares of Common Stock issuable upon the
conversion of such share or shares of Series A Convertible Preferred Stock. To
the extent permitted by law, such conversion shall be deemed to have been
effected and the Conversion Price shall be determined as of the close of
business on the date on which such written notice shall have been received by
the Corporation and the certificate or certificates for such share or shares
shall have been surrendered as aforesaid, and at such time the rights of the
holder of such share or shares of Series A Convertible Preferred Stock shall
cease, and the person or persons in whose name or names any certificate or
certificates for shares of Common Stock shall be issuable upon such conversion
shall be deemed to have become the holder or holders of record of the shares
represented thereby.
<PAGE>
Continuation Sheet 4F
6C. Fractional Shares; Dividends; Partial Conversion. No
fractional shares shall be issued upon conversion of Series A Convertible
Preferred Stock into Common Stock and no payment or adjustment shall be made
upon any conversion on account of any cash dividends on the Common Stock issued
upon such conversion. At the time of each conversion, the Corporation shall pay
in cash an amount equal to all previously declared dividends accrued and unpaid
on the shares of Series A Convertible Preferred Stock surrendered for conversion
to the date upon which such conversion is deemed to take place as provided in
subparagraph 6B, or at the option of the holder, the Corporation shall allow
such dividends to be converted into Common Stock in accordance with and pursuant
to the other terms of this paragraph 6, except that the Conversion Price shall
be the then fair market value of the Common Stock as determined in good faith by
the Board of Directors of the Corporation. In case the number of shares of
Series A Convertible Preferred Stock represented by the certificate or
certificates surrendered pursuant to subparagraph 6A exceeds the number of
shares converted, the Corporation shall, upon such conversion, execute and
deliver to the holder, at the expense of the Corporation, a new certificate or
certificates for the number of shares of Series A Convertible Preferred Stock
represented by the certificate or certificates surrendered which are not to be
converted. If any fractional share of Common Stock would, except for the
provisions of the first sentence of this subparagraph 6C, be delivered upon such
conversion, the Corporation, in lieu of delivering such fractional share, shall
pay to the holder surrendering the Series A Convertible Preferred Stock for
conversion an amount in cash equal to the current market price of such
fractional share as determined in good faith by the Board of Directors of the
Corporation.
6D. Adjustment of Price Upon Issuance of Common Stock. Except
as provided in subparagraph 6E, if and whenever the Corporation shall issue or
sell, or is, in accordance with subparagraphs 6D(1) through 6D(7), deemed to
have issued or sold, any shares of Common Stock for a consideration per share
less than the Conversion Price in effect immediately prior to the time of such
issue or sale, then, forthwith upon such issue or sale, the Conversion Price
shall be reduced to the price determined by dividing (i) an amount equal to the
sum of (a) the number of shares of Common Stock outstanding immediately prior to
such issue or sale multiplied by the then existing Conversion Price and (b) the
consideration, if any, received by the Corporation upon such issue or sale, by
(ii) the total number of shares of Common Stock outstanding immediately after
such issue or sale.
For purposes of this subparagraph 6D, the following subparagraphs 6D(1)
to 6D(7) shall also be applicable:
6D(1) Issuance of Rights or Options. In case at any time the
Corporation shall in any manner grant (whether directly or by assumption
in a merger or otherwise) any warrants or other rights to subscribe
<PAGE>
Continuation Sheet 4G
for or to purchase, or any options for the purchase of, Common Stock or
any stock or security convertible into or exchangeable for Common Stock
(such warrants, rights or options being called "Options" and such
convertible or exchangeable stock or securities being called "Convertible
Securities") whether or not such Options or the right to convert or
exchange any such Convertible Securities are immediately exercisable, and
the price per share for which Common Stock is issuable upon the exercise
of such Options or upon the conversion or exchange of such Convertible
Securities (determined by dividing (i) the total amount, if any, received
or receivable by the Corporation as consideration for the granting of such
Options, plus the minimum aggregate amount of additional consideration
payable to the Corporation upon the exercise of all such Options, plus, in
the case of such Options which relate to Convertible Securities, the
minimum aggregate amount of additional consideration, if any, payable upon
the issue or sale of such Convertible Securities and upon the conversion
or exchange thereof, by (ii) the total maximum number of shares of Common
Stock issuable upon the exercise of such Options or upon the conversion or
exchange of all such Convertible Securities issuable upon the exercise of
such Options) shall be less than the Conversion Price in effect
immediately prior to the time of the granting of such Options, then the
total maximum number of shares of Common Stock issuable upon the exercise
of such Options or upon conversion or exchange of the total maximum amount
of such Convertible Securities issuable upon the exercise of such Options
shall be deemed to have been issued for such price per share as of the
date of granting of such Options or the issuance of such Convertible
Securities and thereafter shall be deemed to be outstanding. Except as
otherwise provided in subparagraph 6D(3), no adjustment of the Conversion
Price shall be made upon the actual issue of such Common Stock or of such
Convertible Securities upon exercise of such Options or upon the actual
issue of such Common Stock upon conversion or exchange of such Convertible
Securities.
6D(2) Issuance of Convertible Securities. In case the
Corporation shall in any manner issue (whether directly or by assumption
in a merger or otherwise) or sell any Convertible Securities, whether or
not the rights to exchange or convert any such Convertible Securities are
immediately exercisable, and the price per share for which Common Stock is
issuable upon such conversion or exchange (determined by dividing (i) the
total amount received or receivable by the Corporation as consideration
for the issue or sale of such Convertible Securities, plus the minimum
aggregate amount of additional consideration, if any, payable to the
Corporation upon the conversion or exchange thereof, by (ii) the total
maximum number of shares of Common Stock issuable upon the conversion or
exchange of all such Convertible Securities)
<PAGE>
Continuation Sheet 4H
shall be less than the Conversion Price in effect immediately prior to the
time of such issue or sale, then the total maximum number of shares of
Common Stock issuable upon conversion or exchange of all such Convertible
Securities shall be deemed to have been issued for such price per share as
of the date of the issue or sale of such Convertible Securities and
thereafter shall be deemed to be outstanding, provided that (a) except as
otherwise provided in subparagraph 6D(3), no adjustment of the Conversion
Price shall be made upon the actual issue of such Common Stock upon
conversion or exchange of such Convertible Securities and (b) if any such
issue or sale of such Convertible Securities is made upon exercise of any
Options to purchase any such Convertible Securities for which adjustments
of the Conversion Price have been or are to be made pursuant to other
provisions of this subparagraph 6D, no further adjustment of the
Conversion Price shall be made by reason of such issue or sale.
6D(3) Change in Option Price or Conversion Rate. Upon the
happening of any of the following events, namely, if the purchase price
provided for in any Option referred to in subparagraph 6D(1), the
additional consideration, if any, payable upon the conversion or exchange
of any Convertible Securities referred to in subparagraph 6D(1) or 6D(2),
or the rate at which Convertible Securities referred to in subparagraph
6D(1) or 6D(2) are convertible into or exchangeable for Common Stock shall
change at any time (including, but not limited to, changes under or by
reason of provisions designed to protect against dilution), the Conversion
Price in effect at the time of such event shall forthwith be readjusted to
the Conversion Price which would have been in effect at such time had such
Options or Convertible Securities still outstanding provided for such
changed purchase price, additional consideration or conversion rate, as
the case may be, at the time initially granted, issued or sold.
6D(4) Stock Dividends. In case the Corporation shall declare a
dividend or make any other distribution upon any stock of the Corporation
payable in Common Stock (except for dividends or distributions upon the
Common Stock), Options or Convertible Securities, any Common Stock,
Options or Convertible Securities, as the case may be, issuable in payment
of such dividend or distribution shall be deemed to have been issued or
sold without consideration.
6D(5) Consideration for Stock. In case any shares of Common
Stock, Options or Convertible Securities shall be issued or sold for cash,
the consideration received therefor shall be deemed to be the amount
received by the Corporation therefor, without deduction therefrom of any
expenses incurred or any underwriting commissions or concessions paid or
allowed by the Corporation in connection therewith. In case any shares of
Common Stock, Options or Convertible
<PAGE>
Continuation Sheet 4I
Securities shall be issued or sold for a consideration other than cash,
the amount of the consideration other than cash received by the
Corporation shall be deemed to be the fair value of such consideration as
determined in good faith by the Board of Directors of the Corporation,
without deduction of any expenses incurred or any underwriting commissions
or concessions paid or allowed by the Corporation in connection therewith.
In case any Options shall be issued in connection with the issue and sale
of other securities of the Corporation, together comprising one integral
transaction in which no specific consideration is allocated to such
Options by the parties thereto, such Options shall be deemed to have been
issued for such consideration as determined in good faith by the Board of
Directors of the Corporation.
6D(6) Record Date. In case the Corporation shall take a record
of the holders of its Common Stock for the purpose of entitling them (i)
to receive a dividend or other distribution payable in Common Stock,
Options or Convertible Securities or (ii) to subscribe for or purchase
Common Stock, Options or Convertible Securities, then such record date
shall be deemed to be the date of the issue or sale of the shares of
Common Stock deemed to have been issued or sold upon the declaration of
such dividend or the making of such other distribution or the date of the
granting of such right of subscription or purchase, as the case may be.
6D(7) Treasury Shares. The disposition of any shares of Common
Stock owned or held by or for the account of the Corporation shall be
considered an issue or sale of Common Stock for the purpose of this
subparagraph 6D.
6E. Certain Issues of Common Stock Excepted. Anything herein
to the contrary notwithstanding, the Corporation shall not be required to make
any adjustment of the Conversion Price in the case of the issuance of up to an
aggregate of 130,000 shares (appropriately adjusted to reflect the occurrence of
any event described in subparagraph 6F) of Common Stock to directors, officers,
employees or consultants of the Corporation in connection with their service as
directors of the Corporation or their employment by the Corporation or any
shares of Common Stock (appropriately adjusted to reflect the occurrence of any
event described in subparagraph 6F) repurchased by the Corporation pursuant to
Stock Restriction Agreements entered into between various individuals and the
Corporation pursuant to the provisions of the Series A Convertible Preferred
Stock Purchase Agreement whereby the Series A Convertible Preferred Stock was
initially issued.
6F. Subdivision or Combination of Common Stock. In case the
Corporation shall at any time subdivide (by any stock split, stock dividend or
otherwise) its outstanding shares of Common Stock into a greater number of
shares, the Conversion
<PAGE>
Continuation Sheet 4J
Price in effect immediately prior to such subdivision shall be proportionately
reduced, and, conversely, in case the outstanding shares of Common Stock shall
be combined into a smaller number of shares, the Conversion Price in effect
immediately prior to such combination shall be proportionately increased.
6G. Reorganization or Reclassification. If any capital
reorganization or reclassification of the capital stock of the Corporation shall
be effected in such a way that holders of Common Stock shall be entitled to
receive stock, securities or assets with respect to or in exchange for Common
Stock, then, as a condition of such reorganization or reclassification, lawful
and adequate provisions shall be made whereby each holder of a share or shares
of Series A Convertible Preferred Stock shall thereupon have the right to
receive, upon the basis and upon the terms and conditions specified herein and
in lieu of the shares of Common Stock immediately theretofore receivable upon
the conversion of such share or shares of Series A Convertible Preferred Stock,
such shares of stock, securities or assets as may be issued or payable with
respect to or in exchange for a number of outstanding shares of such Common
Stock equal to the number of shares of such Common Stock immediately theretofore
receivable upon such conversion had such reorganization or reclassification not
taken place, and in any such case appropriate provisions shall be made with
respect to the rights and interests of such holder to the end that the
provisions hereof (including without limitation provisions for adjustments of
the Conversion Price) shall thereafter be applicable, as nearly as may be, in
relation to any shares of stock, securities or assets thereafter deliverable
upon the exercise of such conversion rights.
6H. Failure to Redeem. If the Corporation fails, for any
reason or for no reason, to redeem on any of the Redemption Dates (as defined in
paragraph 7) the then outstanding shares of Series A Convertible Preferred Stock
to be redeemed in accordance with the terms and conditions of paragraph 7 and if
the Corporation does not obtain the approval of at least sixty-six and
two-thirds percent (66-2/3%) of the then outstanding shares of Series A
Convertible Preferred Stock to such failure, the Conversion Price then in effect
shall be immediately reduced to an amount equal to 95% thereof. Thereafter,
until such redemption has been made in full in accordance with such terms and
conditions, the Conversion Price shall be further reduced on the 90th day
following the Redemption Date and at the end of each 90-day period thereafter by
an amount equal to 5% of the Conversion Price in effect immediately prior to the
first such reduction.
6I. Notice of Adjustment. Upon any adjustment of the
Conversion Price, then and in each such case the Corporation shall give written
notice thereof, by first class mail, postage prepaid, or by telex to non-U.S.
residents, addressed to each holder of shares of Series A Convertible Preferred
Stock at the
<PAGE>
Continuation Sheet 4K
address of such holder as shown on the books of the Corporation, which notice
shall state the Conversion Price resulting from such adjustment, setting forth
in reasonable detail the method upon which such calculation is based.
6J. Other Notices. In case at any time:
(1) the Corporation shall declare any dividend upon its Common
Stock payable in cash or stock or make any other distribution to the
holders of its Common Stock;
(2) the Corporation shall offer for subscription pro rata to
the holders of its Common Stock any additional shares of stock of any
class or other rights;
(3) there shall be any capital reorganization or
reclassification of the capital stock of the Corporation, or a
consolidation or merger of the Corporation with or into, or a sale of all
or substantially all its assets to, another entity or entities; or
(4) there shall be a voluntary or involuntary dissolution,
liquidation or winding up of the Corporation;
then, in any one or more of said cases, the Corporation shall give, by first
class mail, postage prepaid, or by telex to non-U.S. residents, addressed to
each holder of any shares of Series A Convertible Preferred Stock at the address
of such holder as shown on the books of the Corporation, (a) at least 20 days'
prior written notice of the date on which the books of the Corporation shall
close or a record shall be taken for such dividend, distribution or subscription
rights or for determining rights to vote in respect of any such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding up and (b) in the case of any such reorganization, reclassification,
consolidation, merger, sale, dissolution, liquidation or winding up, at least 20
days' prior written notice of the date when the same shall take place. Such
notice in accordance with the foregoing clause (a) shall also specify, in the
case of any such dividend, distribution or subscription rights, the date on
which the holders of Common Stock shall be entitled thereto and such notice in
accordance with the foregoing clause (b) shall also specify the date on which
the holders of Common Stock shall be entitled to exchange their Common Stock for
securities or other property deliverable upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding up, as the case may be.
6K. Stock to be Reserved. The Corporation will at all times
reserve and keep available out of its authorized Common Stock, solely for the
purpose of issuance upon the conversion of Series A Convertible Preferred Stock
as herein provided, such number of shares of Common Stock as shall then be
issuable upon
<PAGE>
Continuation Sheet 4L
the conversion of all outstanding shares of Series A Convertible Preferred
Stock. Before taking any action which would cause an adjustment reducing the
Conversion Price below the then par value of the shares of Common Stock issuable
upon conversion of the Series A Convertible Preferred Stock, the Corporation
will take any corporate action which may, in the opinion of its counsel, be
necessary in order that the Corporation may validly and legally issue fully paid
and nonassessable shares of such Common stock at such adjusted Conversion Price.
6L. No Reissuance of Series A Convertible Preferred Stock.
Shares of Series A Convertible Preferred Stock which are converted into
shares of Common Stock as provided herein shall not be reissued.
6M. Issue Tax. The issuance of certificates for shares of
Common Stock upon conversion of Series A Convertible Preferred Stock shall be
made without charge to the holders thereof for any issuance tax in respect
thereof, provided that the Corporation shall not be required to pay any tax
which may be payable in respect of any transfer involved in the issuance and
delivery of any certificate in a name other than that of the holder of the
Series A Convertible Preferred Stock which is being converted.
6N. Closing of Books. The Corporation will at no time close
its transfer books against the transfer of any Series A Convertible Preferred
Stock or of any shares of Common Stock issued or issuable upon the conversion of
any shares of Series A Convertible Preferred Stock in any manner which
interferes with the timely conversion of such Series A Convertible Preferred
Stock, except as may otherwise be required to comply with applicable securities
laws.
6O. Definition of Common Stock. As used in this paragraph 6,
the term "Common Stock" shall mean and include the Corporation's authorized
Common Stock, par value $.01 per share, as constituted on the date of filing of
these terms of the Series A Convertible Preferred Stock, and shall also include
any capital stock of any class of the Corporation thereafter authorized which
shall not be limited to a fixed sum or percentage of par value in respect of the
rights of the holders thereof to participate in dividends or in the distribution
of assets upon the voluntary or involuntary liquidation, dissolution or winding
up of the Corporation; provided that the shares of Common Stock receivable upon
conversion of shares of Series A Convertible Preferred Stock shall include only
shares designated as Common Stock of the Corporation on the date of filing of
this instrument, or in case of any reorganization or reclassification of the
outstanding shares thereof, the stock, securities or assets provided for in
subparagraph 6G.
6P. Mandatory Conversion. If at any time the Corporation shall
effect a firm commitment underwritten public offering of shares of Common
Stock in which (i) the aggregate price paid
<PAGE>
Continuation Sheet 4M
for such shares by the public shall be at least $4,000,000 and (ii) the price
paid by the public for such shares shall be at least $30.00 per share
(appropriately adjusted to reflect the occurrence of any event described in
subparagraph 6F), then effective upon the closing of the sale of such shares by
the Corporation pursuant to such public offering, all outstanding shares of
Series A Convertible Preferred Stock shall automatically convert to shares of
Common Stock.
7. Redemption. The shares of Series A Convertible Preferred Stock shall be
redeemed as follows:
7A. Mandatory Redemption. Unless the holders of at least
sixty-six and two-thirds percent (66-2/3%) of the then outstanding shares of
Series A Convertible Preferred Stock consent to the delay or waiver of such
redemption, on each of July 1, 1997, July 1, 1998 and July 1, 1999 (each a
"Redemption Date" and collectively the "Redemption Dates"), the Corporation
shall redeem from each holder of shares of Series A Convertible Preferred Stock,
one-third of the shares of Series A Convertible Preferred Stock initially issued
to such holder (or an individual who transferred such shares to the holder) or
acquired by such holder (or an individual who transferred such shares to the
holder) upon exercise of warrants to purchase Series A Convertible Preferred
Stock issued to the holder (or an individual who transferred such shares to the
holder) at the same time the Series A Convertible Preferred Stock was initially
issued.
7B. Redemption Price and Payment. The Series A Convertible
Preferred Stock to be redeemed on each Redemption Date shall be redeemed by
paying for each share in cash an amount equal to $8.16 per share plus, in the
case of each share, an amount equal to all Accruing Dividends unpaid thereon
(whether or not declared) and any other dividends declared but unpaid thereon,
computed to each Redemption Date, such amount being referred to as the
"Redemption Price". Such payment shall be made in full on the Redemption Date to
the holders entitled thereto.
7C. Redemption Mechanics. At least 20 but not more than 30
days prior to each Redemption Date, written notice (the "Redemption Notice")
shall be given by the Corporation by mail, postage prepaid, or by telex to
non-U.S. residents, to each holder of record (at the close of business on the
business day next preceding the day on which each Redemption Notice is given) of
shares of Series A Convertible Preferred Stock notifying such holder of the
redemption and specifying the Redemption Price, the Redemption Date and the
place where said Redemption Price shall be payable. The Redemption Notice shall
be addressed to each holder at his address as shown by the records of the
Corporation. From and after the close of business on each Redemption Date,
unless there shall have been a default in the payment of the Redemption Price,
all rights of holders of shares of Series A Convertible Preferred Stock (except
the right to receive the
<PAGE>
Continuation Sheet 4N
Redemption Price) shall cease with respect to such shares, and such shares shall
not thereafter be transferred on the books of the Corporation or be deemed to be
outstanding for any purpose whatsoever. If the funds of the Corporation legally
available for redemption of shares of Series A Convertible Preferred Stock on
each Redemption Date are insufficient to redeem the total number of outstanding
shares of Series A Convertible Preferred Stock, the holders of shares of Series
A Convertible Preferred Stock shall share ratably in any funds legally available
for redemption of such shares according to the respective amounts which would be
payable with respect to the full number of shares owned by them if all such
outstanding shares were redeemed in full and the Corporation's obligations to
pay the balance of the Redemption Price payable on such Redemption Date shall
continue. The shares of Series A Convertible Preferred Stock not redeemed shall
remain outstanding and entitled to all rights and preferences provided herein.
At any time thereafter when additional funds of the Corporation are legally
available for the redemption of such shares of Series A Convertible Preferred
Stock, such funds will be used, at the end of the next succeeding fiscal
quarter, to redeem the balance of such shares, or such portion thereof for which
funds are then legally available, on the basis set forth above.
7D. Redeemed or Otherwise Acquired Shares to be Retired. Any
shares of Series A Convertible Preferred Stock redeemed pursuant to this
paragraph 7 or otherwise acquired by the Corporation in any manner whatsoever
shall be cancelled and shall not under any circumstances be reissued; and the
Corporation may from time to time take such appropriate corporate action as may
be necessary to reduce accordingly the number of authorized shares of Series A
Convertible Preferred Stock.
8. Amendments. No provision of these terms of the Series A Convertible
Preferred Stock may be amended, modified or waived without the written consent
or affirmative vote of the holders of at least sixty-six and two-thirds percent
(66-2/3%) of the then outstanding shares of Series A Convertible Preferred
Stock.
B. COMMON STOCK
1. Voting Rights. The voting rights of the holders of shares of Common
Stock shall be as set forth in paragraph 2 of Section A of this Article FOURTH.
2. Dividends. Subject to the preferential rights of the Preferred
Stock, the holders of shares of Common Stock shall be entitled to receive, when
and if declared by the Board of Directors, out of the assets of the Corporation
which are by law available therefor, dividends payable either in cash, in
property or in shares of capital stock.
<PAGE>
Continuation Sheet 4O
3. Liquidation. In the event of any liquidation, dissolution or winding
up of the Corporation, whether voluntary or involuntary, after payment shall
have been made to holders of Preferred Stock of the full amounts to which they
shall be entitled as stated and expressed in these Articles of Organization, the
holders of Common Stock shall be entitled, to the exclusion of the holders of
Preferred Stock, to share ratably according to the number of shares of the
Common Stock held by them in all remaining assets of the Corporation available
for distribution to its stockholders.
4. Relative Rights of Preferred Stock and Common Stock. All
preferences, voting powers, relative, participating, optional or other special
rights and privileges, and qualifications, limitations, or restrictions on the
Common Stock are expressly made subject and subordinate to those that may be
fixed with respect to any shares of the Preferred Stock.
<PAGE>
Continuation Sheet 6A
The corporation eliminates the personal liability of each director to the
corporation or its stockholders for monetary damages for a breach of fiduciary
duty as a director notwithstanding any statutory provision or other law imposing
such liability; provided, that noting in this paragraph shall eliminate or limit
the liability of a director (i) for any breach of the director's duty of loyalty
to the corporation or its stockholders, (ii) for acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Sections Sixty-one or Sixty-two of Chapter 156B of the Massachusetts
General laws, or (iv) for any transaction from which the director derived an
improper personal benefit.
Meetings of stockholders may be held anywhere in the United States. Except as
specially provided to the contrary in these Restated Articles of Organization,
the directors may make, amend or repeal the by-laws in whole or in part, except
with respect to any provision thereof which by law, these Articles of the
by-laws requires action by the stockholders and (ii) the whole or any part of
the authorized but unissued shares of capital stock may be issued at any time or
from time to time by the Board of Directors without further action by the
stockholders. The corporation may become a partner or joint venturer in any
business.
ENDOGEN, INC.
EXHIBIT 11.1
Computation of Earnings Per Share
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
November 30, November 30,
1996 1995 1996 1995
---------- --------- ---------- ---------
<S> <C> <C> <C> <C>
Weighted average number of shares outstanding 2,958,746 2,788,458 2,954,866 2,761,542
Shares deemed outstanding from the assumed
exercise of stock options and warrants 298,830 317,436 295,799 299,769
---------- ---------- ---------- ----------
Total 3,257,576 3,105,894 3,250,665 3,061,311
========== ========== ========== ==========
Earnings applicable to common shares $ 153,379 $ 71,948 $ 269,167 $ 96,378
========== ========== ========== ==========
Earnings per share of common stock $ 0.05 $ 0.02 $ 0.08 $ 0.03
========== ========== ========== ==========
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements included in the Form 10-QSB of Endogen, Inc. to which this
exhibit is a part and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<CIK> 0000894020
<NAME> ENDOGEN, INC.
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAY-31-1997
<PERIOD-START> JUN-01-1996
<PERIOD-END> NOV-30-1996
<EXCHANGE-RATE> 1.00
<CASH> 405
<SECURITIES> 0
<RECEIVABLES> 1,606
<ALLOWANCES> 20
<INVENTORY> 1,577
<CURRENT-ASSETS> 3,787
<PP&E> 2,941
<DEPRECIATION> 849
<TOTAL-ASSETS> 6,709
<CURRENT-LIABILITIES> 1,827
<BONDS> 0
0
0
<COMMON> 30
<OTHER-SE> 3,211
<TOTAL-LIABILITY-AND-EQUITY> 6,709
<SALES> 4,704
<TOTAL-REVENUES> 4,704
<CGS> 1,614
<TOTAL-COSTS> 4,265
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 120
<INCOME-PRETAX> 319
<INCOME-TAX> 50
<INCOME-CONTINUING> 269
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 269
<EPS-PRIMARY> .08
<EPS-DILUTED> .08
</TABLE>
